A detailed history of Td Asset Management Inc transactions in Ardelyx, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 105,336 shares of ARDX stock, worth $542,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares
105,336
Previous 195,136 46.02%
Holding current value
$542,480
Previous $1.45 Million 49.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$5.28 - $7.57 $474,144 - $679,786
-89,800 Reduced 46.02%
105,336 $725,000
Q2 2024

Aug 02, 2024

SELL
$5.89 - $9.31 $1.86 Million - $2.93 Million
-315,200 Reduced 61.76%
195,136 $1.45 Million
Q1 2024

May 08, 2024

BUY
$6.05 - $9.74 $1.33 Million - $2.14 Million
219,400 Added 75.41%
510,336 $3.73 Million
Q4 2023

Feb 12, 2024

BUY
$3.29 - $6.64 $57,035 - $115,111
17,336 Added 6.34%
290,936 $1.8 Million
Q3 2023

Oct 27, 2023

BUY
$3.3 - $4.83 $451,440 - $660,744
136,800 Added 100.0%
273,600 $1.12 Million
Q2 2023

Aug 09, 2023

SELL
$3.23 - $4.95 $141,151 - $216,315
-43,700 Reduced 24.21%
136,800 $463,000
Q1 2023

May 10, 2023

BUY
$2.68 - $4.79 $125,692 - $224,651
46,900 Added 35.1%
180,500 $864,000
Q4 2022

Feb 06, 2023

BUY
$1.22 - $2.85 $162,992 - $380,760
133,600 New
133,600 $380,000
Q2 2021

Aug 11, 2021

SELL
$6.55 - $8.98 $584,770 - $801,716
-89,278 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$4.35 - $8.79 $90,914 - $183,710
20,900 Added 30.57%
89,278 $508,000
Q4 2019

Feb 11, 2020

BUY
$4.23 - $8.29 $289,238 - $566,853
68,378 New
68,378 $513,000
Q4 2017

Feb 02, 2018

SELL
$4.85 - $7.8 $115,953 - $186,482
-23,908 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$4.35 - $5.7 $103,999 - $136,275
23,908
23,908 $134,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $796M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.